Avelumab (MSB0010718C; anti-PD-L1) vs platinum-based doublet as first-line treatment for metastatic or recurrent PD-L1-positive non-small-cell lung cancer: The phase 3 JAVELIN Lung 100 trial.

Chand, Vikram; Ozguroglu, Mustafa; Helwig, Christoph; Cuillerot, Jean-Marie; Westeel, Virginie; Reck, Martin; DeGreen, Hyatt P.; Rose, Andrea L.; Pavlakis, Nick; Derjcke, Sofie Maria; Radic, Jasna; Jeppesen, Nina; Thomas, Michael; Losonczy, Gyorgy; Kalinka-Warzocha, Ewa; Dreosti, Lydia Mary; Postmus, Pieter E.

dc.contributor.author	Chand, Vikram
dc.contributor.author	Ozguroglu, Mustafa
dc.contributor.author	Helwig, Christoph
dc.contributor.author	Cuillerot, Jean-Marie
dc.contributor.author	Westeel, Virginie
dc.contributor.author	Reck, Martin
dc.contributor.author	DeGreen, Hyatt P.
dc.contributor.author	Rose, Andrea L.
dc.contributor.author	Pavlakis, Nick
dc.contributor.author	Derjcke, Sofie Maria
dc.contributor.author	Radic, Jasna
dc.contributor.author	Jeppesen, Nina
dc.contributor.author	Thomas, Michael
dc.contributor.author	Losonczy, Gyorgy
dc.contributor.author	Kalinka-Warzocha, Ewa
dc.contributor.author	Dreosti, Lydia Mary
dc.contributor.author	Postmus, Pieter E.
dc.date.accessioned	2021-03-03T15:19:43Z
dc.date.available	2021-03-03T15:19:43Z
dc.identifier.citation	Reck M., DeGreen H. P. , Rose A. L. , Pavlakis N., Derjcke S. M. , Radic J., Jeppesen N., Thomas M., Losonczy G., Kalinka-Warzocha E., et al., "Avelumab (MSB0010718C; anti-PD-L1) vs platinum-based doublet as first-line treatment for metastatic or recurrent PD-L1-positive non-small-cell lung cancer: The phase 3 JAVELIN Lung 100 trial.", Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Illinois, Amerika Birleşik Devletleri, 3 - 07 Haziran 2016, cilt.34
dc.identifier.other	vv_1032021
dc.identifier.other	av_3e6cd881-aac6-4f0b-836a-2e9cf65ec0b4
dc.identifier.uri	http://hdl.handle.net/20.500.12627/45825
dc.identifier.uri	https://doi.org/10.1200/jco.2016.34.15_suppl.tps9105
dc.language.iso	eng
dc.subject	Dahili Tıp Bilimleri
dc.subject	İç Hastalıkları
dc.subject	Onkoloji
dc.subject	Klinik Tıp (MED)
dc.subject	Tıp
dc.subject	Sağlık Bilimleri
dc.subject	Klinik Tıp
dc.subject	ONKOLOJİ
dc.title	Avelumab (MSB0010718C; anti-PD-L1) vs platinum-based doublet as first-line treatment for metastatic or recurrent PD-L1-positive non-small-cell lung cancer: The phase 3 JAVELIN Lung 100 trial.
dc.type	Bildiri
dc.contributor.department	, ,
dc.identifier.volume	34
dc.contributor.firstauthorID	149190

Bu öğenin dosyaları:

Dosyalar	Boyut	Biçim	Göster
Bu öğe ile ilişkili dosya yok.

Bu öğe aşağıdaki koleksiyon(lar)da görünmektedir.

Bildiri [64839]

Basit öğe kaydını göster